To: Buck who wrote (10066 ) 8/26/1998 10:01:00 PM From: David Respond to of 26039
Buck, I don't think the stock price has come about as a result of ASCOM. We have seen average to below average volume in the stock, as a matter of fact, not higher than average, which could indicate distribution. We certainly haven't seen bad news announced out of IDX that would justify a major price break. What is the intrinsic value of the company? Salomon put a value on ANADAC last December of about $2.25 per share (by the way, it was acquired for about $.25 per share in 1992, a very good investment). With growth continuing, I think that the valuation would be more like $2.50 -- excluding GSA sales, which belong in the AFIS segment. Then there is the TP-600, AFIS business. We still don't have a 10K out, so it is pretty hard to determine how this is going, but there was a recent statement out of Fowler, I think, that placed product sales (mainly AFIS, that is) at $65 million per year. The AFIS business is growing at about 40% per year, or more on a base of, I'm guessing now in the absence of a new 10K, about $55-60 million. I would say the market is presently valuing this area of business at, perhaps, another $2.50 per share, or at a ratio of about 1 times sales. That is quite low, in my opinion, for a clearly profitable segment with a solid growth rate and very little in the way of competitive threats. In fact, margins here are probably increasing. That leaves the bio-ID business. And there is some, if not a lot, in security and access for prisons and banks. More than there is for other biometric companies that have had the press releases over the past six months. Let's give that business, which is growing (although it hasn't broken through) a P/S ratio of 2, or about $.50 per share. In fact, this segment may be negatively valued right now, since it is soaking up profits from the TP-600 sales. That adds up to $5.50. Do these seem like reasonable valuations to you? They don't to me. What it does tell me, though, is that there is a chance for a qualitative change in the IDX share price with any breakthrough announcement, since it would force fundamental revaluations by the analysts. Even without a big O'Hare or Oracle announcement, for example, or even an INS deal, I think this stock is underpriced. But in the small-cap, high-tech bear market we're now in, that kind of correction can take a while to get through. David PS -- I don't see any competitors with profits or, in most cases, with any significant revenues whatsoever. IDX is running at close to $100 million in revenues, and increasing revenues at an extremely high rate.